The information in this section is intended solely for the medical and pharmaceutical industry and may only be used in professional activities.
ARE YOU A MEDICAL AND/OR A PHARMACEUTICAL WORKER?
(Choosing an answer, you are responsible for the accuracy of the information provided)
YES, I am a medical/pharmaceutical worker
NO, I am not a medical/pharmaceutical worker
LOGUFEN
PHARMACEUTICAL FORM :
Oral solution
ATC class :
N03A Х14
Active substance :
LEVETIRACETAM
Composition: :
1 ml of solution contains levetiracetam 100 mg;
excipients: liquid maltitol (Е 965), methyl parahydroxybenzoate (Е 218), propyl parahydroxybenzote (Е 216), glycerol, acesulfame potassium (Е 950), citric acid anhydrous, sodium citrate, sodium dihydrogen phosphate, dihydrate, sodium hydroxide, flavor “Lemon”, purified water.
Indications for use:
Monotherapy (first-choice drug) in the treatment of: - partial seizures with or without secondary generalization in adults and adolescents from 16 years of age with newly diagnosed epilepsy. As adjunctive therapy in the treatment of: - partial seizures with or without secondary generalization in adults and children from 1 month of age with epilepsy; • myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy; • primary generalized tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalized epilepsy.
